Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | RPMI 8226 is a human multiple myeloma cell line derived from the peripheral blood of a 61-year-old male patient with IgG-type myeloma. The cell line exhibits a lymphoblast-like morphology and grows in suspension culture as single cells or loose cell aggregates. RPMI 8226 cells secrete free immunoglobulin light chains (λ chains) and retain key cellular characteristics of malignant plasma cells. Cytogenetically, the cell line displays an aneuploid karyotype with complex chromosomal alterations—including the t(14;16) translocation and TP53 gene mutations—that drive its aggressive phenotype. Due to its well-defined genomic profile and stable growth characteristics, RPMI 8226 has become a widely recognized in vitro model for investigating the pathogenesis of multiple myeloma, evaluating novel targeted therapies and chemotherapeutic agents, exploring mechanisms of resistance to proteasome inhibitors, and conducting high-throughput drug screening. |
| Tissue | Peripheral blood / Bone marrow |
| Disease | Multiple Myeloma; Plasma Cell Leukemia |
| Morphology | Lymphoblast-like |
| Gender | Male |
| Age | 61 years |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Research on the pathogenesis of multiple myeloma, malignant plasma cell proliferative disorders, and MAF oncogene signaling pathways; 2. Evaluation and screening of anti-myeloma drugs, immunomodulatory drugs (IMiDs), and proteasome inhibitors; 3. Research on mechanisms of chemotherapy resistance and apoptosis pathways; 4. Functional genomics analysis, target validation, and CRISPR/Cas9 screening and validation. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Aneuploid |
| Tumorigenic | Yes, forms tumors in immunocompromised (nude/SCID) mice |
| Genetic Profile | t(14;16)(q32;q23) translocation (IGH/MAF fusion); TP53 mutation; KRAS mutation |
| Expression Markers | Secretes immunoglobulin free light chains (lambda light chain); CD38 positive; CD138 positive; PCA-1 positive |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Maintain the culture by adding fresh medium or replacing the medium. 2. Establish the culture by centrifuging (1,000 rpm, 5 minutes) and resuspending the cells (at a density of 2 × 10⁵ to 4 × 10⁵ viable cells/mL). 3. Do not allow the cell concentration to exceed 1 × 10⁶ cells/mL. 4. Gently resuspend the cells to prepare a single-cell suspension before subculturing into a new culture vessel. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | Maintain cell density between 2 × 10⁵ and 1 × 10⁶ cells/mL (split ratio approximately 1:2 to 1:4) |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0642 | Luciferase Reporter Cell Line - RPMI 8226 | Inquiry |
| CSC-RO01644 | OVAL Stable Cell Line - RPMI 8226 | Inquiry |
| CSC-RO01897 | GFP/OVAL Stable Cell Line - RPMI 8226 | Inquiry |
| CSC-RO02150 | Luc/OVAL Stable Cell Line - RPMI 8226 | Inquiry |
| CSC-RO02403 | GFP/Luc/OVAL Stable Cell Line - RPMI 8226 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.